查詢結果分析
相關文獻
- 乳癌標靶治療新藥賀疾妥Pertuzumab
- The Effects of Pesticides Chlordane, Dieldrin and Endosulfan on the Growth of Human Breast Cancer Cell Lines MCF-7 and SK-BR-3
- Prognostic Factors in Node-Negative Breast Cancer Patients: The Experience in Taiwan
- Cystic Hypersecretory Intraductal Carcinoma of the Breast--Case Report
- Timing of Shoulder Exercise after Modified Radical Mastectomy: A Prospective Study
- 前哨淋巴掃描診斷乳癌早期轉移
- Measurement of the Quality of Life during Different Clinical Phases of Breast Cancer
- The Prognostic Significance of Pathologic Characteristics of Breast Cancer Patients in Taiwan
- 趨勢面分析法在癌症地圖繪製上的應用: 以臺灣的乳癌死亡率為例
- 使用Tamoxifen治療乳癌
頁籤選單縮合
題名 | 乳癌標靶治療新藥賀疾妥Pertuzumab=Pertuzumab: A Novel Drug of Targeted Therapy for Breast Cancer |
---|---|
作者 | 宋立文; 姚昌甫; 黃志偉; 謝政智; Sun, Li-wen; Yao, Chang-fu; Huang, Chih-wei; Hsieh, Cheng-chih; |
期刊 | 藥學雜誌 |
出版日期 | 20170300 |
卷期 | 33:1=130 2017.03[民106.03] |
頁次 | 頁46-51 |
分類號 | 418.31 |
語文 | chi |
關鍵詞 | 乳癌; 標靶治療藥物; 新輔助性化療; Pertuzumab; Trastuzumab; |
中文摘要 | Pertuzumab 是全新的乳癌標靶藥物,與 trastuzumab 作用機轉不同,pertuzumab 能阻斷 HER2和其他 HER 家族成員進行配體依賴型之異質二聚化作用,使得癌細胞 MAPK 激酶路徑與 PI3K 激酶路徑之訊息傳遞無法正常運作,導致癌細胞停止生長與 自我凋亡。除此之外,pertuzumab 更藉由調節抗體依賴型細胞媒介之細胞毒性作用 (ADCC) 將腫瘤細胞殺死。當 pertuzumab 與 trastuzumab 及 docetaxel 併用,雙標靶合 併化學治療,作為治療轉移後未曾接受抗 HER2或化學療法之 HER2陽性轉移性乳癌 病人,中位數總存活期長達56.5個月,比對照組 (以安慰劑取代 pertuzumab) 足足多 了15.7個月。同樣的組合用於 HER2陽性乳癌患者手術前之新輔助性化療,也有高達 45.8%達到病理學上的完全緩解,5年無惡化存活率更高達86%。 |
英文摘要 | Pertuzumab is a novel drug of targeted therapy for breast cancer, blocks liganddependent heterodimerization of HER2 with other HER family members. As a result, pertuzumab inhibits ligand-initiated intracellular signaling through MAPK and PI3K, that can result in cell growth arrest and apoptosis, respectively. In addition, pertuzumab mediates antibody-dependent cell-mediated cytotoxicity (ADCC). When given pertuzumab in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who had not received prior anti-HER2 therapy or chemotherapy for metastatic disease, the median overall survival was 56.5 months, with an increase of 15.7 months. The same combination for the preoperative neoadjuvant treatment of patients with HER2-positive breast cancer, the pathological complete response rate was 45·8%, and the 5-year progression-free survival rate was up to as high as 86%. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。